

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/547,843
Filing Date	September 6, 2005
First Named Inventor	Takashi HORIGUCHI
Art Unit	1649
Examiner Name	CHERNYSHEV, OLGA N
Attorney Docket Number	Q101074

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
		Peter SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", Nature, 1992, 359: 325-327.	N
		Eric R. SIEMERS, MD. et al., "Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid- β After Inhibition of γ -Secretase", Clinical Neuropharmacology, 2007, 30(6): 317-325.	N
		Eric SIEMERS, MD. et al., "Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ -Secretase Inhibitor in Volunteers", Clin. Neuropharmacol, 2005, 28(3): 126-132.	N
		Adam S. FLEISHER, MD. et al., "Phase 2 Safety Trial Targeting Amyloid β Production with a γ -Secretase Inhibitor in Alzheimer Disease", Arch Neurol, 2008, 65(8): 1031-1038.	N
		M.G. SPILLANTINI et al., "Different configurational states of β -amyloid and their distributions relative to plaques and tangles in Alzheimer disease", Proc. Natl. Acad. Sci. USA, 1990, 87: 3947-3951.	N

EXAMINER SIGNATURE

Examiner Signature	Date Considered
/Olga Chernyshev/	12/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/